부산대학교 도서관

Wenying Deng,1,* Zeyi Zhao,1,* Tao Zou,2 Tongdong Kuang,3,* Jing Wang1,* 1School of Basic Medical Sciences, University of South China, Hengyang, Hunan Province, 421001, People’s Republic of China; 2Department of Cardiovascular Medicine, First Affiliated Hospital of University of South China, Hengyang, Hunan Province, 421001, People’s Republic of China; 3Guangxi Key Laboratory of Diabetic Systems Medicine, Guilin Medical University, Guilin, Guangxi Province, 541199, People’s Republic of China*These authors contributed equally to this workThese authors contributed equally to this studyCorrespondence: Tongdong Kuang, Guangxi Key Laboratory of Diabetic Systems Medicine, Guilin Medical University, Guilin, 541199, People’s Republic of China, Email 594536067@qq.com Jing Wang, School of Basic Medical Sciences, University of South China, Hengyang, Hunan Province, 421001, People’s Republic of China, Tel +86 15200735915, Email 738212405@qq.comAbstract: Diabetes mellitus (DM) is a chronic metabolic disease characterized by elevated blood glucose levels, resulting in multi-organ dysfunction and various complications. Fusion proteins can form multifunctional complexes by combining the target proteins with partner proteins. It has significant advantages in improving the performance of the target proteins, extending their biological half-life, and enhancing patient drug compliance. Fusion protein-based drugs have emerged as promising new drugs in diabetes therapeutics. However, there has not been a systematic review of fusion protein-based drugs for diabetes therapeutics. Hence, we conducted a comprehensive review of published literature on diabetic fusion protein-based drugs for diabetes, with a primary focus on immunoglobulin G (IgG) fragment crystallizable (Fc) region, albumin, and transferrin (TF). This review aims to provide a reference for the subsequent development and clinical application of fusion protein-based drugs in diabetes therapeutics.Keywords: diabetes mellitus, fusion protein, Fc protein, glucagon-like peptide 1 receptor agonists, transferrin, albumin